MILPITAS, Calif., April 14, 2016 -- Nanometrics Incorporated (NASDAQ:NANO), a leading provider of advanced process control systems, today announced the launch of Atlas® III, its latest flagship system for optical critical dimension (OCD) and thin film process control. Working in close collaboration with its launch partner, the company recently delivered multiple Atlas III systems to enable manufacturing of next-generation advanced memory devices. Additional Atlas III systems will be delivered to other leading customers in the second quarter of 2016 for advanced 7nm/5nm foundry, 1X DRAM and third-generation 3D-NAND process development.
The Atlas III delivers improvements in metrology capability and cost of ownership, and can further increase productivity and accelerate yield when combined as part of a unified fleet with Nanometrics’ industry-leading NanoDiffract® OCD software and IMPULSE® integrated metrology solutions. The Atlas III incorporates a proprietary combination of spectroscopic reflectometry and spectroscopic ellipsometry solutions that enable precise control of every critical process step, providing yield-relevant insight into complex structure profiles across etch, clean, deposition and chemical mechanical polish (CMP) steps. The Atlas III extends the company’s track record of offering the industry’s leading common platform for both OCD and thin film measurements, enabling flexibility for customers in deployment and ramp to reduce cost of ownership, while providing consistent metrology performance for next-generation device process control.
Continued device scaling, use of novel materials and processes, and the emergence of high-aspect-ratio device architectures, such as those found in advanced logic, DRAM and 3D-NAND devices, all place increasing demands on process equipment and control, driving the need for better precision and accuracy. Additionally, tighter process tolerances are requiring more complex metrology including direct in-die SRAM measurements, as well as across complex arrays in memory devices. By extending metrology performance to sub-angstrom precision and accuracy levels, the Atlas III system enables advanced process control (APC) across a broad range of applications in high-volume manufacturing.
“The Atlas III system architecture of combined measurement technology and proprietary analysis algorithms provides the broadest range of semiconductor fab application metrology solutions and the richest data set, enabling the most complex measurements,” commented Dr. Srini Vedula, vice president of OCD/Thin Film Solutions at Nanometrics. “The new system significantly extends the capability of our industry-leading Mueller Matrix-based spectroscopic ellipsometry and spectroscopic reflectometry solution. Combined with the latest advancements in our NanoDiffract software, the Atlas III will be utilized at the most demanding front-end-of-line applications in transistor formation, storage capacitor, and 3D-NAND tier stack applications to accelerate information cycles in development, enabling APC on critical layers to improve yield of these new technologies, all while reducing cost of ownership with high productivity.”
Since its initial launch in 2004, multiple generations of the Atlas system have been deployed across every fab segment for advanced logic, DRAM, 3D-NAND, advanced non-volatile memory, CMOS image sensor and power device manufacturing.
About Nanometrics
Nanometrics is a leading provider of advanced, high-performance process control metrology and inspection systems used primarily in the fabrication of semiconductors and other solid-state devices, including sensors, optoelectronic devices, high-brightness LEDs, discretes and data storage components. Nanometrics’ automated and integrated metrology systems measure critical dimensions, device structures, topography and various thin film properties, including three-dimensional features and film thickness, as well as optical, electrical and material properties. The company’s process control solutions are deployed throughout the fabrication process, from front-end-of-line substrate manufacturing, to high-volume production of semiconductors and other devices, to advanced three-dimensional wafer-level packaging applications. Nanometrics’ systems enable advanced process control for device manufacturers, providing improved device yield at reduced manufacturing cycle time, supporting the accelerated product life cycles in the semiconductor and other advanced device markets. The company maintains its headquarters in Milpitas, California, with sales and service offices worldwide. Nanometrics is traded on NASDAQ Global Select Market under the symbol NANO. Nanometrics’ website is http://www.nanometrics.com.
Forward Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those described in this release. Although Nanometrics believes that the expectations reflected in the forward-looking statements are reasonable, actual results could differ materially from these expectations due to a variety of factors, including, but not limited to, shifts in the timing of product deliveries, the failure to achieve improved processes, the rate of adoption of our products, customer spending plans, and general economic conditions. For additional information and considerations regarding the risks faced by Nanometrics that could cause actual results to differ materially, see its annual report on Form 10-K for the year ended December 26, 2015, as filed with the Securities and Exchange Commission on February 24, 2016, including under the caption “Risk Factors,” as well as other periodic reports filed with the SEC from time to time. Nanometrics disclaims any obligation to update information contained in any forward-looking statement, except as required by law.
Investor Relations Contact: Claire McAdams Headgate Partners LLC 530.265.9899 [email protected] Company Contact: Kevin Heidrich Nanometrics 408.545.6000 [email protected]


Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
FDA Approves Mitapivat for Anemia in Thalassemia Patients
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Italy Fines Apple €98.6 Million Over App Store Dominance
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 



